Pfizer Inc. maintained sales forecasts for the company’s pandemic products on May 3 after a series of hikes to revenue projections for its COVID-19 vaccine in 2021, in a sign that dizzying growth has slowed.
Moderna Inc.’s chief medical officer said on Sunday the company’s vaccine for children under 6 years old will be ready for review by a Food and Drug Administration panel when it meets in June.
COVID’s new Omicron sub-lineages can dodge immunity from past infection, study says
BNT162b2 (Pfizer and BioNTech), Clinical Trials, COVID-19 Antibodies, COVID-19 shots, COVID-19 Vaccines, Covid-19 Variants, Janssen COVID-19 Vaccine (J&J), Omicron (B.1.1.529) (South Africa), R&D, Scientists, South AfricaTwo new sublineages of the Omicron coronavirus variant can dodge antibodies from earlier infection well enough to trigger a new wave, but are far less able to thrive in the blood of people vaccinated against COVID-19, South African scientists found.
AstraZeneca topped off a very busy week with the company’s first-quarter 2022 financial report, citing a total of $11.39 billion in revenue, a whopping increase of 60 percent. That performance was driven by the acquisition of Alexion and several contracts for Vaxzevria, AstraZeneca’s COVID-19 vaccine developed with the University of Oxford.
AstraZeneca’s COVID-19 vaccine still has market potential despite an expected global oversupply of shots and delays in the vaccine’s approval in the United States, the company’s chief executive Pascal Soriot said on April 29.
A shareholder proposal calling on Moderna Inc. to study transferring production of COVID-19 vaccines to less-developed countries won 24 percent support from investors on April 28 after the company received a rare endorsement from the World Health Organization.
Merck makes waves in Q1 2022 with COVID-19 treatment, cancer portfolio
Breakthrough Therapy Designation, Business, COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Earnings per share (EPS), Financials, Forecasts, Keytruda, Market Share, Merck, Pneumococcal Conjugate Vaccines, Pneumococcal Vaccines, Sales, TherapeuticsMerck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.
Moderna files for U.S. authorization of COVID shot for kids under 6
Children, Coronavirus Vaccines, COVID-19 Vaccines, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), Omicron BA.2, Pediatric, Pediatric Patients, Pediatric Vaccines, Pediatrics, Pediatrics, TherapeuticsModerna Inc. asked U.S. regulators to authorize the company’s COVID-19 vaccine for children under the age of 6, which would make it the first shot against the coronavirus available for those under 5-years-old.
GSK’s strong Q1 driven by COVID-19, returning demand for shingles vaccine
Antibodies, Business, Business Intelligence, Consumer Health Care, Consumer Healthcare, Coronavirus Disease 2019 (COVID-19), Earnings per share (EPS), Financials, GlaxoSmithKline, Guidance, Leadership, Operations, Presentations, Quarterly results, Sales, Sales, Sales & Marketing, Sales Guidance, Shingles, Strikes, Therapeutics, VaccinesGlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
The Rockefeller Foundation injects $55 million to get Covid-19 shots from airports to arms
Africa, Asia, Caribbean, Coronavirus Disease 2019 (COVID-19), Coronavirus Vaccines, COVID-19 public health emergency, COVID-19 shots, COVID-19 Vaccinations, COVID-19 Vaccines, Foundations, Initiatives, Latin America, Public Health, Public Health Emergencies, Rockefeller Foundation, Therapeutics, VaccinationsThe Rockefeller Foundation announced the launch of the Global Vaccination Initiative, a $55 million investment over two years to support country-led efforts to fully vaccinate 90% of the most at-risk populations in Africa, Asia, Latin America, and the Caribbean.